Insights from an Italian Prospective Cohort Study

Marica Iommi,Francesca Gonnelli,Martina Bonifazi,Andrea Faragalli,Federico Mei,Marco Pompili,Flavia Carle,Rosaria Gesuita

DOI: https://doi.org/10.3390/jcm13092727

IF: 3.9

2024-05-07

Journal of Clinical Medicine

Abstract:Background: Pirfenidone and Nintedanib have significantly improved the prognosis of patients with idiopathic pulmonary fibrosis (IPF), reducing mortality risk and exacerbations. This study aimed to analyze antifibrotic treatment utilization and its association with clinical outcomes (i.e., acute exacerbation or death) during 2014–2021 in newly diagnosed IPF patients, using Healthcare Utilization Databases of the Marche Region, Italy. Methods: The first 12-month adherence to antifibrotic was estimated using the Proportion of Days Covered (PDC), defining adherence as PDC ≥ 75%. State Sequence Analysis over the initial 52 weeks of treatment was used to identify adherence patterns. The role of adherence patterns on acute exacerbations/death, adjusted by demographic, clinical features, and monthly adherence after the 52-week period (time-dependent variable), was assessed with Cox regression. Results: Among 667 new IPF cases, 296 received antifibrotic prescriptions, with 62.8% being adherent in the first year. Three antifibrotic utilization patterns emerged—high adherence (37.2%), medium adherence (42.5%), and low adherence (20.3%)—with median PDCs of 95.3%, 79.5%, and 18.6%, respectively. These patterns did not directly influence three-year mortality/exacerbation probability, but sustained adherence reduced risk over time. Conclusions: Good adherence was observed in in this population-based study, emphasizing the importance of continuous antifibrotics therapy over time to mitigate adverse outcomes.

medicine, general & internal

What problem does this paper attempt to address?

This paper aims to explore the compliance patterns of patients with idiopathic pulmonary fibrosis (IPF) in antifibrotic treatment and their association with clinical outcomes (such as acute exacerbation or death). Specifically, the study utilized data from the Marche region's medical utilization database in Italy from 2014 - 2021 to analyze the use of antifibrotic treatment among newly - diagnosed IPF patients from 2014 - 2019 and its impact on clinical outcomes.

### Research Background
- **Disease Background**: Idiopathic pulmonary fibrosis (IPF) is a rare, chronic, and progressive disease that mainly affects the elderly, manifested as dyspnea and decline in lung function, with a poor prognosis.
- **Treatment Methods**: Currently, there are two antifibrotic drugs available in Italy: Pirfenidone and Nintedanib. These two drugs have been approved for clinical use since 2014 and 2016 respectively, and have significantly improved the prognosis of patients, reducing the risk of death and acute exacerbation.

### Research Objectives
- **Primary Objective**: To analyze the compliance patterns of newly - diagnosed IPF patients in antifibrotic treatment from 2014 - 2021 and their association with clinical outcomes (acute exacerbation or death).
- **Specific Questions**:
- Evaluate the antifibrotic treatment compliance of newly - diagnosed IPF patients in the first year.
- Identify different compliance patterns and their impact on clinical outcomes.
- Analyze the intolerance to antifibrotic treatment and its related factors.

### Methods
- **Data Sources**: Use the Marche region's medical utilization database, including the Regional Beneficiary Database (RBD), Hospital Discharge Records (HDR), Drug Prescription Database (DP), and Outpatient Care Database (OCD).
- **Compliance Evaluation**: Evaluate compliance by calculating the Proportion of Days Covered (PDC) within 12 months, with PDC ≥ 75% defined as compliant.
- **State Sequence Analysis (SSA)**: Describe the individual's antifibrotic treatment compliance pattern through the weekly PDC values.
- **Statistical Analysis**: Use statistical methods such as the Kaplan - Meier method and Cox regression model for analysis.

### Results
- **Overall Compliance**: Among 667 newly - diagnosed IPF patients, 296 received antifibrotic treatment, of which 62.8% showed good compliance in the first year.
- **Compliance Patterns**: Three main antifibrotic treatment compliance patterns were identified:
- High compliance (37.2%), medium compliance (42.5%), low compliance (20.3%).
- **Clinical Outcomes**: The high - compliance pattern did not directly reduce the risk of death or acute exacerbation within three years, but continuous high compliance could significantly reduce the risk.
- **Intolerance**: Female, elderly, and patients with poorer health conditions were more likely to have drug intolerance.

### Conclusions
- **Main Conclusions**: Among newly - diagnosed IPF patients, approximately two - thirds of the patients showed good antifibrotic treatment compliance in the first year. Continuous high compliance can significantly reduce the risk of death or acute exacerbation, while low compliance does not have this protective effect.
- **Practical Significance**: The study emphasizes the importance of continuous antifibrotic treatment and points out the need to strengthen the supervision and management of patients with low compliance to improve the treatment effect.

### Keywords
- Idiopathic pulmonary fibrosis; Antifibrotic treatment; Drug use patterns; Compliance; Medical utilization database

Hope this information is helpful for you to understand this paper! If you have more specific questions, feel free to continue asking.